MultiCell Technologies Inc. (OTC:MCET) acquired the rights to the Ideal BioStent resorbable coronary stent for an undisclosed amount. The buyout, via Woonsocket, Rhode Island-based MultiCell’s ...
WOONSOCKET, R.I., July 11, 2011 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) ("MultiCell") today announced that it entered into a sponsored research agreement with ...
A three-alarm fire Tuesday burned the administrative building of an Oro Valley industrial business for several hours, officials said. The fire began shortly after 9 a.m. in a work area located in the ...
MultiCell Technologies, Inc. and Living Cell Technologies Limited (LCT) have announced that the parties have entered into a joint venture to develop therapeutic liver cell applications. The ...
MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional ...
WOONSOCKET, R.I., Aug. 10, 2012 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) is pleased to announce the updated preclinical research results for MCT-465 and MCT-485. MCT-485 ...
WOONSOCKET, R.I., Aug. 6, 2013 -- /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) and Genisphere LLC will collaborate on the development of targeted MCT-485 nanoparticle ...
LOS ANGELES, Jan. 27, 2025 /PRNewswire/ -- Partillion Bioscience Corporation ("Partillion"), a life science tools company, announced the opening of pre-orders for its Nanovial Multicell Assay Antibody ...
MultiCell Technologies Inc. (OTCQB:MCET - News) stock volume soared Mar. 3, with 41,190,256 shares changing hands, significantly higher than its three-month average volume of 30,444,778 shares. What ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results